VALIDATION PUBLICATIONS & ABSTRACTS

Validation Data


Evidence / Validation

Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests

Publication: ESMO BREAST CANCER CONGRESS 2022 Authors Esther Schuler(1), Sahra Uygun(2), Lorenza Mittempergher(3), Darina Pronin(3), Sammy Mee(2), Simon Bao(2), Tyson Cavness(2), Anke Witteveen(3), and Annuska Glas(3) 1. Zotz|Klimas, MVZ Düsseldorf-Centrum GbR, Germany 2. Agendia Inc., Irvine, CA 3. Agendia NV., Amsterdam, Netherlands Background The MammaPrint® 70-gene signature (70GS) risk Read More

High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer

Publication: J Surg Oncol. 2022;125:596–602. Authors: Jennifer A. Crozier, MD et al. Title: High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer Abstract Background: With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients Read More

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

PUBLICATION: SABCS 2020 AUTHORS: Joseph McKelley, Jennifer Wei, Brian Hoxeng, Andrea Menicucci, Erin Yoder, Shiyu Wang, William Audeh Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. With goals of minimizing potential exposure to SARS-COV-2, as well as resource rationing, physicians are urged Read More

ESMO 2020 – Hallmarks of Cancer

PUBLICATION: ESMO 2020 AUTHORS: Josien C. Haan, Rajith Bhaskaran, Lorenza Mittempergher, Ersan Lujinovic, William Audeh, Frederique Penault-Llorca and Annuska M. Glas Background: MammaPrint® (MP) is a 70-gene based assay that stratifies early-stage breast cancer (EBC) patients into low and high-risk of relapse. BluePrint® (BP) is an 80-gene based assay that Read More

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

PUBLICATION: Translational Oncology Volume 13, Issue 4, April 2020, 100756 AUTHORS: Lorenza Mittempergher, Leonie JMJ Delahaye, Anke T Witteveen, Mireille HJ Snel, Sammy Mee, Bob Y Chan, Christa Dreezen, Naomi Besseling, Ernest JT Luiten, Annuska M Glas SUMMARY: The analytical performance of a multi-gene diagnostic signature depends on many parameters, Read More